No Data
No Data
No Data
No Data
No Data
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting Download as PDF March 19, 2024 7:30am EDT PRINCETON
Sonnet BioTherapeuticMar 19 07:30 ET
RNLX, ASLN and SONN Among Pre-market Losers
Seeking AlphaMar 12 08:28 ET
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
US equities were in red territory after Monday's opening bell as traders looked ahead to the consumer inflation report due for release later in the week for clues on the direction of the Federal Reser
MT NewswiresMar 11 09:49 ET
Top Premarket Gainers
Kidpik Corp. (PIK) shares soared more than three-fold Monday premarket following a 5.9% gain in the previous session. The L.S. Starrett Company (SCX) shares surged 56% after the company agreed to a ta
MT NewswiresMar 11 08:44 ET
Express News | Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Moomoo 24/7Mar 11 07:47 ET
Express News | Sonnet BioTherapeutics Says Early Safety Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy Met Study's Initial Pre-Specified Objective
Moomoo 24/7Mar 11 07:35 ET
No Data
No Data